Prednisone, cyclophosphamide

Small molecule

CChinese Academy of Medical Sciences, Fuwai Hospital

Prednisone, cyclophosphamide is one of 18 small molecule programs targeting Takayasu arteritis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Takayasu ArteritisActive, not recruiting

Takayasu ArteritisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Takayasu Arteritis

#DrugCompanyPhaseTrials

Cellcept

Humira

3 3

Xeljanz

PPrism Pharmaceuticals

Approved

1 4

Actemra

Roche

Phase 3

4 5

Rayos

RRoxane Laboratories

Approved

—6

Imuran

LLegacy Health System

Approved

—7

Cytoxan

BBaxter Healthcare Corporation

Rinvoq

1 9

Stelara

Johnson & Johnson

Phase 3

1 10

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Takayasu arteritis1 trial

Anti-inflammatory Treatment for Inactive Takayasu Arteritis

Unknown status·—·Phase 2/3·NCT03550781·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prednisone, cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prednisone, cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prednisone, cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chinese Academy of Medical Sciences, Fuwai Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CChinese Academy of Medical Sciences, Fuwai Hospital

Prednisone, cyclophosphamide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Takayasu arteritis1 trial

References

Drug Info

Quick Facts

Related News